Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Anti-CD19 Chimeric Antigen Receptor T Cells（PZ01） for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

NCT03281551 is registered in ClinicalTrials.gov with Pinze Lifetechnology Co. Ltd. as lead sponsor.

NCT NCT03281551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03281551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Anti-CD19 Chimeric Antigen Receptor T Cells（PZ01） for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Lead sponsor
Pinze Lifetechnology Co. Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2017
Completion date
November 1, 2020
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, b-cell lymphoma